420 with CNW — Marijuana ETFs See Green as Hopes for Federal Marijuana-Policy Reform Rise

Cannabis Exchange-Traded Funds (ETFs) surged in value in September as positive federal action renewed investor interest in the cannabis industry. Shortly after the U.S. Department of Health and Human Services recommended that the Drug Enforcement Administration (DEA) reclassify cannabis to Schedule III from Schedule I and ease federal marijuana restrictions, marijuana-related ETFs began to soar as investors started investing in the cannabis industry.

America’s state-legal cannabis sector is the fastest-growing sector in the nation, generating billions of dollars in yearly revenue. However, the industry has been consistently handicapped by federal regulation. Federal law still classifies cannabis as a Schedule I drug with no medical application, which has made operating in the state-level industry extremely difficult. Issues like limited access to banking services and federal financial aid are prevalent throughout the industry and have likely prevented investors from investing in the cannabis sector.

For example, the Poseidon Dynamic Cannabis ETF by AdvisorShares went down in August amid declining investor interest in marijuana. The fund’s comanager Morgan Paxhia said at the time that the closure of the fund was partly due to a “dramatic shift in investor sentiment” that has affected the nation’s state-level marijuana industry.

Now that federal lawmakers are flirting with the idea of decriminalizing and possibly legalizing the quasilegal sector at the federal level, investor interest is rising. Last week, AdvisorShares Pure US cannabis (MSOS) was up by 56% and ETFMG Alternative Harvest (MJ) soared by 47% while both the SP 500 and the Dow Jones Industrial Average were up by just around 0.5%,

Matt Bottomley, an analyst from financial services firm Canaccord Genuity, noted that federal headlines often act as catalysts for how certain stocks trade. He observed that recent cannabis-related headlines had a positive effect on cannabis ETFs.

The Biden administration’s recommendation for cannabis reclassification at the federal level also caused the shares of cannabis companies such as Cronos Group, Tilray Brands and Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) to surge. This has been a boon for cannabis equities, which have suffered from a capital crunch in recent years as many investors withdrew from the industry.

Despite extensive legalization at the state level, federal prohibition has consistently been a thorn in the cannabis industry’s side, limiting the sector’s access to financing and preventing it from expanding to broader markets. The prospect of finally legalizing cannabis at the federal level and eliminating the barriers that limit trade in the sector will likely attract more investors to cannabis-related equities.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Spokesperson Says Biden Supports Medical Marijuana as Cannabis Scheduling Review Progresses

President Joe Biden’s stance on the medical use of marijuana has been unequivocal, as affirmed by the White House amid an ongoing federal review of cannabis scheduling. In a recent press briefing, Karine Jean-Pierre, White House press secretary, addressed inquiries regarding the potential ramifications of reclassifying marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).

The U.S. Department of Health and Human Services (HHS) recently recommended this reclassification to the U.S. Drug Enforcement Administration (DEA).

Jean-Pierre, exercising caution, refrained from preempting the process. She emphasized, “I don’t want to anticipate events; I’ve encountered this query previously.” She clarified, “Let me be clear: The president directed both the HHS secretary and the attorney general to initiate the administrative evaluation of marijuana’s scheduling, as you have outlined.”

Nonetheless, Jean-Pierre reiterated the president’s endorsement of federal cannabis reform, particularly concerning medical marijuana. Biden’s support for cannabis reform has not been unwavering. During his tenure as a senator, he championed legislation that intensified the war on drugs.

Should the DEA concur with HHS’s Schedule III recommendation, it would signify a pivotal shift in federal cannabis policy. The reclassification would acknowledge that cannabis possesses low potential for abuse and offers medical utility. However, it would not endorse existing state-level medical marijuana programs. Nevertheless, it would facilitate expanded research into the plant and have substantial implications for the marijuana industry.

Bipartisan congressional representatives have applauded the health agency’s recommendation, viewing it as a significant stride toward federal legalization. Some have even claimed credit for this advancement, citing their years of advocacy for marijuana reform.

Despite the enthusiasm surrounding this development, the scheduling decision remains tentative. The DEA has stated that it will initiate its review, factoring in findings from the FDA. Ultimately, the DEA retains the authority to decide on the reclassification to Schedule III.

From a political perspective, moving cannabis from Schedule I to III would allow the president to assert his role in achieving a substantial reform, facilitating an administrative evaluation more than half a century after cannabis was categorized as the most restrictive substance during the government’s war on drugs. However, it would not fulfill his campaign promise to decriminalize cannabis.

The reform could also invigorate momentum for congressional initiatives aimed at altering federal marijuana laws, such as the cannabis banking reform bill listed among the legislative priorities of Chuck Schumer, the Senate Majority Leader, according to a recent Dear Colleague letter.

As broader cannabis policy reforms take shape, industry actors such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) could be poised for explosive growth as the market is opened across the country.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Acquires High Times Intellectual Property, Featured in Financial News Media Article

Lucy Scientific Discovery (NASDAQ: LSDI) today announced the acquisition of the intellectual property (“IP”) of High Times, an iconic brand in the cannabis industry. In addition to the Hightimes.com domain, the transaction also includes the trademarks for the Cannabis Cup and 420.com brands and their respective domain names. In exchange, High Times will receive a 19.9% stake in Lucy’s outstanding stock as well as performance-based payments.

“Lucy expects this acquisition to drive high margin revenue quickly and sustainably across the cannabis sector around the world. This is a great opportunity to grow the market presence of the nearly 50-year-old High Times brand globally through licensing and online distribution,” Lucy Scientific Discovery Executive Chairman and CEO Richard Nanula stated in the news release. “We are confident that this opportunity can add significant value for our shareholders.”

In addition, Lucy Scientific Discovery (NASDAQ: LSDI) was featured in a Financial News Media article together with other companies active in the burgeoning global cannabis market, including SNDL Inc. (NASDAQ: SNDL), Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED), Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), and Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY). The piece discusses opportunities in the market driven by increased legalization of cannabis and rising acceptance of its use for medical purposes. Statista projects that revenue in the global cannabis market is projected to reach US$51.27 billion in 2023, at an annual growth rate (“CAGR” 2023-2028) of 14.95%, resulting in a market volume of US$102.90 billion by 2028.

To view the full press release/article, visit https://cnw.fm/IdURM and https://cnw.fm/FjOGd

About Lucy Scientific Discovery Inc.

Lucy Scientific Discovery is a Nasdaq-listed company with holdings and operations in a variety of psychotropic businesses. The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. Lucy Scientific Discovery Inc. and its wholly-owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada). This specialized license authorizes LSDI to develop, sell, deliver, and manufacture pharmaceutical-grade active pharmaceutical ingredients (“APIs”) used in controlled substances and their raw material precursors. With a focus on pioneering innovative therapies for patients in need, Lucy Scientific Discovery Inc. is dedicated to advancing the understanding and applications of psychotropic medicines, improving mental health outcomes, and enhancing well-being for individuals worldwide. For more information, visit the company’s website at www.LucyScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to LSDI are available in the company’s newsroom at https://cnw.fm/LSDI

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Suggests Minor Cannabinoids Could Treat Skin Ailments

Recent research suggests that lesser-known cannabinoids derived from marijuana and hemp, such as CBN, CBM, CBC, CBDV and THCV, might hold promise in treating dermatological conditions INCLUDING acne, psoriasis and eczema. The study, published recently in the peer-reviewed journal “Molecules,” highlights the potential therapeutic value of these minor cannabinoids in managing skin disorders as well as presenting new avenues for patient care and well-being enhancement.

The research, led by Polish scholars Dorota Kowalczuk and Emilia Kwiecień, involved an extensive review of existing scientific literature. The team observed that minor cannabinoids exhibit a range of pharmacological activities, encompassing anti-itch, analgesic, antimicrobial and anti-inflammatory properties. These cannabinoids have also shown efficacy in alleviating symptoms linked to various dermatological issues, including pruritus, acne, eczema and psoriasis.

Some minor cannabinoids appeared particularly suited for targeting specific skin conditions. For instance, CBDV, due to its anti-inflammatory characteristics, can potentially soothe itching and inflammation related to atopic dermatitis. Additionally, its antioxidant properties could aid in healing acne lesions.

Similarly, other recently identified cannabinoids such as CBE and CBM display anti-inflammatory potential and open new avenues for research into targeted disease conditions. CBC, known for its anti-inflammatory and antioxidant effects, may offer benefits for treating psoriasis, acne and atopic dermatitis.

THCV stands out for its potential in combating acne because it appears to regulate sebum production. Its anti-inflammatory and antibacterial attributes contribute to alleviating inflammation and targeting bacteria linked to acne development.

The researchers highlighted the therapeutic potential of minor cannabinoids, including cannabinol (CBN), cannabigerol (CBG), cannabigerolic acid (CBGA), tetrahydrocannabivarin (THCV), cannabichromene (CBC), cannabidiforol (CBDP) and cannabidivarin (CBDV), as well as newer discoveries such as cannabielsoin (CBE) and cannabimovone (CBM).

The effects are believed to stem from interactions between cannabinoids and the body’s endocannabinoid system, a central regulatory mechanism crucial for maintaining organism health and function. This system plays a pivotal role in regulating skin functions, immune responses, cell differentiation, proliferation and survival, thereby effectively mitigating skin inflammation. Furthermore, topical application of these minor cannabinoids may hold promise for mitigating aging-related effects on the skin.

However, the researchers caution that more in-depth research is essential to validate their safety and effectiveness. Multiple challenges, including impact on the nervous system, product quality and regulation concerns, and ethical and legal considerations, need comprehensive exploration.

They concluded that despite the encouraging therapeutic potential, the utilization of cannabinoids, particularly minor ones, requires continued research, stringent regulations and a balanced approach to maximize benefits while minimizing any potential risks to health and society.

Companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) selling marijuana for both medical and recreational use could be helping people combat more symptoms or conditions than the patients themselves intend.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — New CBD Law in California Draws Industry-Wide Attention

Last week, the governor of California signed into law a reform that opens the state’s economy globally to manufacturers of hemp-derived CBD products. The bill the governor signed, dubbed AB45, creates a framework for the manufacture and sale of hemp-derived products in the state.

The measure will allow hemp-derived CBD products to be sold to the state’s adult-use or medical cannabis retailers, with forecasts showing that those stores will hit sales of between $4.8 billion and $5.7 billion this year. Canopy Growth Corp.’s (TSX: WEED) (NASDAQ: CGC) head of lobbying, David Culver, states that officials had been working on this measure for more than two years.

Canopy Growth is involved in the manufacture of CBD products derived from hemp, which include a line of CBD gummies and Biosteel sports drinks. However, the company hasn’t been selling those products in California because the state’s cannabis policy didn’t allow the sale of over-the-counter CBD products.

In an interview, Culver stated that the measure would open up the state’s market and offer regulatory certainty for retailers in California to assure them that their products for sale won’t be confiscated or seized. Back in 2018, a ban on hemp-derived CBD in drinks and dietary supplements and food led to product seizures and occasional raids.

CV Sciences senior vice president of scientific and regulatory affairs Doug MacKay stated that before the 2018 ban, the company had been operating successfully in California and had built a lot of relationships. CV Sciences is involved in the manufacture and sale of hemp-derived CBD products. It sells its products in CVS drugstores and other countrywide retailers. After the ban, the company, which is based in California, had to stop distributing its products in brick-and-mortar shelves in the state.

MacKay applauds cannabis and hemp negotiators for not giving up until a compromise for the sale of CBD products was reached. In his statement, he noted that the measure marked a clear pathway to the market and afforded retailers a clear way to work with other CBD companies that are willing to have the right labeling and follow the laws.

However, not everyone is happy with the measure, as the ban on smokable hemp is still intact, which leaves hemp farmers at a disadvantage. National Industrial Hemp Council spokesperson Larry Farnsworth stated that the measure would affect hemp farmers in the state who grow smokable hemp flower. Some hemp producers in the state have even threatened to file a lawsuit over the new measure.

Those grumbles notwithstanding, the passing of the CBD law in California is likely to broaden the market for leading manufacturers of CBD products.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Medical Marijuana Shares Off to a Great Start on London Stock Exchange

Marijuana shares in the UK have been rising quickly, with investors now looking toward a new investment class in the market: medical marijuana shares.

Last week, MGC Pharma, which is London’s first marijuana stock, debuted on the London Stock Exchange. The firm raised £6.5 million ($9 million) on its premiere, with the stock moving to 4.25p (59 cents) a share from a 1.475p (25 cents) per share opening price. This left the company with a market cap of more than £75 million ($104 million).

In a way, the increase in the London stock mirrored the American market, when investors from Reddit’s r/WallStreetBets forced the price of various marijuana stocks to rise on the back of an Aphria and Tilray merger. The likelihood of President Joe Biden’s administration federally legalizing the marijuana industry has also helped.

Tilray Inc. (NASDAQ: TLRY) rose by 50%, which added more than $2 billion in value to the company’s stock. This upped the company’s yearly gains to more than 670%. Other companies that have recorded significant gains this year are Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), which has increased by more than 120% so far; Aphria Inc. (NASDAQ: APHA), which was up by 280%; and Canopy Growth Corp. (TSX: WEED) (NYSE: CGC), which rose by 110%.

So far, London has been slow to launch medical marijuana IPOs. However, following MGC Pharma’s remarkable reception last week after a two-year campaign by Memery Crystal, a London law firm, attitudes may at last be changing.

Up until now, regulators and banks were concerned that marijuana businesses would be seen as almost-criminal enterprises; turns out, this may not be the case. Memery Crystal CEO, Nick Davis, who is also an advocate campaigning for the medicinal use of marijuana, stated that after MGC Pharma’s successful IPO, he received calls from America, Canada and Israel, all from companies that wanted to list in the United Kingdom.

Over in the United States, medical marijuana is legal in 30 states. Projections from Prohibition Partners show that by 2024, the country’s market will be valued at $37.9 billion. The firm also estimates that by 2024, nearly 340,000 patients in the UK will be using marijuana treatments. Additionally, their research states that by 2024, UK’s legal marijuana market will be valued at nearly £2.3 billion.

In the UK, research focused on the medical applications of marijuana is still in the early stages. Many are hopeful, however, that London may soon become the right place for the growing marijuana market to raise funds to finance further medical studies and research. However, advocates are still emphasizing that the whole point of this is not to help individuals get high but to help manage pain and relieve human suffering.

Furthermore, guidelines from the National Institute for Health Care and Excellence asserted that the medication from MGC Pharma was effective, which assisted in moving things along.

Back in the States, Gage Growth Corp. (d.b.a. Gage Cannabis) , which operates within the Michigan marijuana market, has initiated a number of steps intended to grow its brand. For example, the compamy has exclusive brand partnerships with some of the most recognizable brands, such as Cookies, across the country. Such partnerships are likely to see the company grow more rapidly than its competitors.

NOTE TO INVESTORS: The latest news and updates relating to Gage Growth Corp. (d.b.a. Gage Cannabis) are available in the company’s newsroom at https://cnw.fm/GAGE

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) Announces Corporate Updates, New Strategic Focus

Canopy Rivers (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, on Friday provided an update on its 49%-owned joint venture, PharmHouse Inc. Per the update, on Oct. 29, 2020, PharmHouse received a court order from the Ontario Superior Court of Justice to initiate a sale and investment solicitation process (“SISP”) to identify interest in, and opportunities for, a sale of, or investment in, all or part of PharmHouse’s assets or business. This may include a restructuring, recapitalization, or other form of reorganization of PharmHouse’s business and affairs. Phase one of the SISP concluded on Nov. 30, 2020, and a number of non-binding offers were received. PharmHouse, with the assistance of the monitor and the SISP advisor, has selected a number of parties to bring forward to the next phase of the SISP, and binding offers for phase two are due on or about Feb. 16, 2021.

In addition, Canopy Rivers today announced its entry into a definitive agreement with Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) pursuant to which, among other things, Canopy Rivers will transfer three portfolio assets to Canopy Growth in exchange for $115 million in cash and 3,750,000 common shares of Canopy Growth and the cancellation of all 36,468,318 Multiple Voting Shares (“MVS”) and the 15,223,938 Subordinate Voting Shares (“SVS”) of Canopy Rivers held by Canopy Growth (collectively, the “transaction”). On closing, the transaction will result in Canopy Rivers becoming a widely-held company and will unlock substantial value, providing it with significant additional cash resources and allowing it to pursue opportunities in the global cannabis market, including the United States. “This is a transformative transaction for our company that we believe provides substantial value to our shareholders through an enhanced cash position and strategic flexibility, and the collapse of our dual class share structure,” said Narbe Alexandrian, president and CEO of Canopy Rivers. “Following the closing of the transaction, we intend to shift our focus to pursuing other opportunities in the global cannabis market, where we believe that our new strategic focus and substantial balance sheet will allow us to successfully execute our revamped strategic plan.”

To view the full press releases, visit https://cnw.fm/fcsm3 and https://ccw.fm/vGdez

About Canopy Rivers Inc.

Canopy Rivers is a venture capital firm specializing in cannabis with a portfolio of 18 companies across various segments of the cannabis value chain. The company believes that bringing together people, capital and ideas raises the potential of the entire cannabis industry. By leveraging industry insights, in-house expertise and thesis-driven approach to investing, Canopy Rivers aims to provide shareholders exposure to specialized and disruptive cannabis companies. Canopy Rivers’ mission is to invest in innovators across the cannabis value chain, help them grow, and ultimately create value by guiding these companies towards a monetization event. Together with its portfolio, the company is helping build the cannabis industry of tomorrow, today. For more information, visit www.CanopyRivers.com.

NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://cnw.fm/RIV

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

CannabisNewsBreaks – Benzinga Cannabis Capital Conference Goes Digital to Connect Even More Industry Insiders, Enthusiasts

The ninth installment of the Benzinga Cannabis Capital Conference is switching to a virtual experience. Originally scheduled to take place in Chicago, the now entirely digital event is set to take place on October 15, 2020, and will feature an array of presentations, quick-fire keynotes and panel discussions with top cannabis insiders. The Cannabis Capital Conference of 2020 will feature presentations from companies such as Cresco Labs Inc. (OTCQX: CRLBF), Canopy Growth Corporation (NYSE: CGC), Trulieve Cannabis Corp. (OTCQX: TCNNF), SLANG Worldwide Inc. (OTCQB: SLGWF), Entheon Biomedical, and many more. A new landscape for Benzinga, the shift to virtual events has proven successful in its ability to connect even more individuals from anywhere in the world. “We’ve all participated in some clunky virtual events over the past months and this was smooth with strong contacts and ‘meetings,’” Michael Mills, president and CEO of Body and Mind, said of Benzinga’s digital format. “Really appreciate all [of Benzinga’s] work!”

To view the full press release, visit https://cnw.fm/7uIOl

About Benzinga

Benzinga is a leading financial media company dedicated to making information easier to consume. Benzinga’s news desk is constantly breaking stories and moving billions of dollars of market capitalization through its real-time news tool, Benzinga Pro. Benzinga’s original content is syndicated to 70 partner websites including Yahoo! Finance, MSN, CNNMoney, Fox Business and MarketWatch. For more information or to register for the Virtual Cannabis Capital Conference, visit www.Benzinga.com.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsAudio – Pac Roots Cannabis Corp. (CSE: PACR) Employs Cutting-Edge Genetics to Deliver Premium Products

CannabisNewsWire Editorial Coverage: As the cannabis industry matures and is again heating up — a recent eye-popping report by Data Bridge Market Research projects that the global legal marijuana market will explode to more than $90 billion by 2027. Companies operating in the sector are looking to capitalize on opportunities the multibillion-dollar space offers. Recognizing the often submarginal quality of available product as well as high cost of development and land acquisition, Pac Roots Cannabis Corp. (CSE: PACR) (PACR Profile) utilizes state-of-the-art genetics to ensure premium-quality products. Using science and key strategic partnerships, Pac Roots intends to eliminate the quality and cost barriers to success and carve what could be profitable niche in a booming market. Canopy Growth Corporation (NYSE: CGC) continues expansion of its Canadian operations while Cronos Group Inc. (NASDAQ: CRON) has officially entered the Israeli medical cannabis market with the sale of its dried flower products. Aphria Inc. (NASDAQ: APHA) has also entered the Israeli market with its recently announced supply agreement with Canndoc, and Organigram Holdings Inc. (NASDAQ: OGI) has launched Trailblazer Snax, the largest cannabis-infused chocolate bar in Canada.

To hear the AudioPressRelease, visit http://cnw.fm/XHwyi

To view the full editorial, visit http://cnw.fm/dfp4F

About Pac Roots Cannabis Corp.

Pac Roots is focused on delivering the finest genetics to Canadians. Preserving the excellence of its elite strains while introducing the highest quality of new strains to the public is the company’s passion. The foundation, based on genetic variation and stability, drives the decision making for Pac Roots Cannabis Corp.’s business. For more information about the company, visit www.PacRoots.ca.

NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://cnw.fm/PACR

About CannabisNewsAudio

CannabisNewsAudio, a service of CannabisNewsWire (CNW), allows you to sit back and listen to market updates, interviews and company press releases. CannabisNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. CannabisNewsAudio is a complimentary service of CannabisNewsWire.

For more information, visit www.CannabisNewsAudio.com.

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – One Cannabis Door Closes, New Ones Open for Former Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) CEO

Former Canopy Growth (TSX: WEED) (NYSE: CGC) co-founder and co-CEO Bruce Linton was featured in a recent Yahoo! Finance article by Zack Guzman. The piece details “a smattering of new roles” Linton has landed within the cannabis industry since being “ousted” by Canopy’s board, which Guzman describes as having become increasingly controlled by investor and beer conglomerate Constellation Brands Inc. (NYSE: STZ). The cannabis pioneer will reportedly be joining, in an advisor capacity, many smaller companies, as well as “trying his hand as an activist investor” for SLANG Worldwide Inc. (OTC: SLGWF) – a global cannabis consumer packaged goods company. Among his multitude of new roles, Linton will serve as executive chairman for Michigan-based Gage Cannabis and as special advisor for animal health and wellness CBD micro-cap Better Choice Company Inc. (OTCQB: BTTR). The article quotes Linton on his new endeavors, where he states, “The way I selected the companies was not how much equity they would give me. I turned down the most self-enriching offers. However to be transparent, all firms provided me with generous equity exposure. With each firm and space, I sought to develop a specific view of how we build enterprise value from the current activities and limit disruption.”

To view the full article, visit http://cnw.fm/9iihd

About Canopy Growth Corporation

Canopy Growth is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and capsule forms, as well as medical devices through Canopy Growth’s subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.

Canopy Growth’s medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and has devoted millions of dollars toward cutting-edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics.

Canopy Growth operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships.

From its historic public listing on the Toronto Stock Exchange and New York Stock Exchange to its international expansion, pride in advancing shareholder value through leadership is engrained in all accomplishments at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, as well as lifestyle guru Martha Stewart and Fortune 500 alcohol leader Constellation Brands, to name but a few. For more information visit www.CanopyGrowth.com.

About CanadianCannabisWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

CanadianCannabisWire is part of the InvestorBrandNetwork.